ME02492B - Lapatanib za lečenje kancera - Google Patents
Lapatanib za lečenje kanceraInfo
- Publication number
- ME02492B ME02492B MEP-2016-168A MEP16816A ME02492B ME 02492 B ME02492 B ME 02492B ME P16816 A MEP16816 A ME P16816A ME 02492 B ME02492 B ME 02492B
- Authority
- ME
- Montenegro
- Prior art keywords
- hla
- lapatinib
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
Claims (15)
1.Lapatinib, ili njegova farmaceutski prihvatljiva so ili farmaceutska kompozicija, za upotrebu u lečenju kancera kod čoveka, naznačen time, što je za pomenutog ispitanika utvrđeno da nije nosilac jednog ili više alelnih polimorfizama izabranih iz grupe koju čine: HLA-DQA1*0201, HLA-DQB1*0202, i/ili HLA-DRB1*0701.
2.Lapatinib, ili njegova farmaceutski prihvatljiva so ili farmaceutska kompozicija, za upotrebu u lečenju kancera kod čoveka prema patentnom zahtevu 1, naznačen time što je za pomenutog ispitanika utvrđeno da nije nosilac najmanje dva polimorfizma izabrana iz grupe koju čine: HLA-DRB1*0701, HLA-DQA1*0201, i/ili HLA-DQB1*0202.
3.Lapatinib, ili njegova farmaceutski prihvatljiva so ili farmaceutska kompozicija, za upotrebu u lečenju kancera kod čoveka prema patentnom zahtevu 1 ili patentnom zahtevu 2, naznačen time, što se pomenuti lapatinib ili njegova farmaceutski prihvatljiva so ili farmaceutska kompozicija, primenjuje zajedno sa najmanje još jednim antikancerskim agensom.
4.Lapatinib, ili njegova farmaceutski prihvatljiva so ili farmaceutska kompozicija, za upotrebu u lečenju kancera kod čoveka prema patentnom zahtevu 3, naznačen time, što je pomenuti, najmanje jedan, dodatni antikancerski agens izabran iz grupe koju čine: trastuzumab, kapecitabin, paklitaksel, karboplatin, pazopanib i letrozol.
5.Lapatinib, ili njegova farmaceutski prihvatljiva so ili farmaceutska kompozicija, za primenu kod tretirane populacije humanih ispitanika obolelih od kancera, naznačen time, što je pomenuta tretirana populacija izabrana iz početne populacije humanih ispitanika obolelih od kancera i što ima smanjeni procenat ispitanika koji su nosioci polimorfnog HLA alela izabranog iz grupe koju čine: HLA-DQA1*0201, HLA-DQB1*0202 i HLA-DRB1*0701 u poređenju sa početnom populacijom.
6.Lapatinib, ili njegova farmaceutski prihvatljiva so ili farmaceutska kompozicija, za upotrebu u lečenju čoveka obolelog od kancera prema bilo kojem od patentnih zahteva od 1 do 5, naznačen time što je za pomenutog ispitanika takođe utvrđeno da nije nosilac polimorfizama i/ili genotipova rs12153855 i/ili rs17207923 na TNXB genu.
7.Postupak ispitivanja (skrininga) humanog ispitanika obolelog od kancera kao pomoć u predviđanju pojave hepatotoksičnosti povezane sa lapatinibom ili njegovom farmaceutski prihvatljivom soli ili farmaceutskom kompozicijom, koji obuhvata određivanje da li ispitanik ima HLA genotip izabran iz grupe koju čine: HLA-DQA1*0201, HLA-DQB1*0202 i HLA-DRB1*0701, naznačen time što prisustvo takvog HLA genotipa ukazuje na povišen rizik od hepatotoksičnosti povezane sa lapatinibom ili njegovom farmaceutski prihvatljivom soli ili farmaceutskom kompozicijom kod pomenutog humanog ispitanika, u poređenju sa rizikom očekivanim kod opšte populacije.
8.Postupak prema patentnom zahtevu 7 dalje obuhvata utvrđivanje postojanja međusobne povezanosti otkrivanja HLA-DQA1*0201, HLA-DQB1*0202 i/ili HLA-DRB1*0701 alela i povišenog rizika od pojave hepatotoksičnosti povezane sa lapatinibom ili njegovom farmaceutski prihvatljivom soli ili farmaceutskom kompozicijom.
9.Postupak prema patentnom zahtevu 7 ili prema patentnom zahtevu 8, dalje obuhvata određivanje da li je pomenuti ispitanik nosilac genotipa HLA-B*4403, i/ili rs12153855 i/ili rs17207923 na TNXB genu.
10.Postupak prema bilo kojem od patentnih zahteva od 7 do 9 dalje obuhvata određivanje da li je pomenuti ispitanik DQ2.2. seropozitivan.
11.Postupak identifikacije humanog ispitanika obolelog od kancera kod koga postoji povišeni rizik od hepatotoksičnosti povezane sa terapijskim režimom primene lapatiniba, ili njegove farmaceutski prihvatljive soli ili farmaceutske kompozicije, obuhvata: a.izvođenje tehnike genotipizacije na biološkom uzorku poreklom od pomenutog ispitanika u cilju određivanja da li HLA genotip humanog ispitanika uključuje alel izabran iz grupe koju čine: HLA-DQA1*0201, HLA-DQB1*0202 ili HLA-DRB1*0701; b.detektovanje HLA-DQA1*0201, HLA-DQB1*0202 i/ili HLA-DRB1*0701; i c.utvrđivanje postojanja međusobne povezanosti otkrivanja HLA-DQA1*0201, HLA-DQB1*0202 i/ili HLA-DRB1*0701 alela i povećanog rizika od pojave hepatotoksičnosti povezane sa terapijskim režimom primene lapatiniba, ili njegove farmaceutski prihvatljive soli ili farmaceutske kompozicije, u poređenju sa rizikom u slučaju da nijedan od HLA-DQA1*0201, HLA-DQB1*0202 i/ili HLA-DRB1*0701 alela nije otkriven.
12.Postupak prema patentnom zahtevu 11 naznačen time što je pomenuti ispitanik nosilac oba, i HLA-DQA1*0201 i HLA-DQB1*0202 polimorfizma.
13. Postupak prema patentnom zahtevu 11 ili patentnom zahtevu 12, naznačen time, što dalje obuhvata izvođenje tehnike genotipizacije na biološkom uzorku poreklom od pomenutog ispitanika u cilju određivanja da li pomenuti ispitanik ima genotipove rs12153855 i/ili rs17207923 na TNXB genu i utvrđivanje postojanja međusobne povezanosti otkrivanja genotipova rs12153855 i/ili rs17207923 na TNXB genu i povišenog rizika od pojave hepatotoksičnosti povezane sa lapatinibom ili njegovom farmaceutski prihvatljivom soli ili farmaceutskom kompozicijom, u poređenju sa rizikom u slučaju da nijedan od genotipova rs12153855 i/ili rs17207923 na TNXB genu nije otkriven.
14.Lapatinib, ili njegova farmaceutski prihvatljiva so ili farmaceutska kompozicija, za upotrebu u lečenju kancera kod čoveka prema bilo kojem od patentnih zahteva od 1 do 6, ili postupak prema bilo kojem od patentnih zahteva od 11 do 13, naznačen time, što je utvrđeno da je pomenuti ispitanik DQ2.2. seropozitivan.
15. Lapatinib, ili njegova farmaceutski prihvatljiva so ili farmaceutska kompozicija, za upotrebu u lečenju čoveka obolelog od kancera prema bilo kojem od patentnih zahteva od 1 do 6 ili 14, ili postupak prema bilo kojem od patentnih zahteva od 7 do 13, naznačen time, što pomenuti kancer predstavlja kancer dojke.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23594709P | 2009-08-21 | 2009-08-21 | |
| US30756910P | 2010-02-24 | 2010-02-24 | |
| EP10810654.3A EP2467140B1 (en) | 2009-08-21 | 2010-08-20 | Lapatinib for treating cancer |
| PCT/US2010/046142 WO2011022633A2 (en) | 2009-08-21 | 2010-08-20 | Method of threating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02492B true ME02492B (me) | 2017-02-20 |
Family
ID=43607603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2016-168A ME02492B (me) | 2009-08-21 | 2010-08-20 | Lapatanib za lečenje kancera |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US20120156200A1 (me) |
| EP (1) | EP2467140B1 (me) |
| JP (1) | JP5876827B2 (me) |
| KR (1) | KR101781658B1 (me) |
| CN (1) | CN102770140B (me) |
| AU (2) | AU2010284092A1 (me) |
| BR (1) | BR112012003653A2 (me) |
| CA (2) | CA3080511C (me) |
| CY (1) | CY1118486T1 (me) |
| DK (1) | DK2467140T3 (me) |
| EA (1) | EA027959B1 (me) |
| ES (1) | ES2589377T3 (me) |
| HR (1) | HRP20161110T1 (me) |
| HU (1) | HUE029098T2 (me) |
| IL (1) | IL218230B (me) |
| LT (1) | LT2467140T (me) |
| ME (1) | ME02492B (me) |
| MX (1) | MX367580B (me) |
| PL (1) | PL2467140T3 (me) |
| PT (1) | PT2467140T (me) |
| RS (1) | RS55074B1 (me) |
| SG (2) | SG10201405039VA (me) |
| SI (1) | SI2467140T1 (me) |
| SM (1) | SMT201600296B (me) |
| WO (1) | WO2011022633A2 (me) |
| ZA (1) | ZA201201110B (me) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101648787B1 (ko) | 2009-09-28 | 2016-08-17 | 치루 파머수티컬 컴퍼니 리미티드 | 타이로신 키나제 억제제로서 유용한 4－（치환된 아닐리노）－퀴나졸린 유도체 |
| CA2863287A1 (en) * | 2012-01-31 | 2013-08-08 | Smithkline Beecham (Cork) Limited | Method of treating cancer |
| GB201403820D0 (en) | 2014-03-04 | 2014-04-16 | Isis Innovation | Assay |
| CN104293958B (zh) * | 2014-10-16 | 2016-09-21 | 卫生部北京医院 | 一种预测强直性脊柱炎易感性的试剂盒和方法 |
| WO2018111662A1 (en) * | 2016-12-14 | 2018-06-21 | Merck Sharp & Dohme Corp. | Human genetic markers associated with response to treatments that target clostridium difficile toxin b |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4582788A (en) | 1982-01-22 | 1986-04-15 | Cetus Corporation | HLA typing method and cDNA probes used therein |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5871918A (en) | 1996-06-20 | 1999-02-16 | The University Of North Carolina At Chapel Hill | Electrochemical detection of nucleic acid hybridization |
| US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| EP0897567A2 (en) | 1996-04-19 | 1999-02-24 | Spectra Biomedical, Inc. | Correlating polymorphic forms with multiple phenotypes |
| AR007857A1 (es) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen. |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| KR100815681B1 (ko) | 2000-06-30 | 2008-03-20 | 글락소 그룹 리미티드 | 퀴나졸린 디토실레이트 염 화합물 |
| US20070281041A1 (en) * | 2004-03-02 | 2007-12-06 | Introgen Therapeutics, Inc. | Compositions and Methods Involving MDA-7 for the Treatment of Cancer |
| US7794960B2 (en) * | 2004-06-04 | 2010-09-14 | Glaxosmithkline Llc | Predictive biomarkers in cancer therapy |
| JP2007117085A (ja) * | 2005-09-28 | 2007-05-17 | Genodive Pharma Kk | 塩酸チクロピジンの副作用である肝臓障害の発生危険率の検査方法 |
| EP1988164A4 (en) | 2006-02-23 | 2009-04-22 | Univ Kanazawa Nat Univ Corp | METHOD FOR TESTING THE SENSITIVITY OF A SOLID TUMOR AGAINST TYROSINE KINASE INHIBITOR AND TEST KIT THEREFOR |
| US20090192101A1 (en) * | 2006-11-22 | 2009-07-30 | Mien-Chie Hung | Cancer-specific promoters |
| US20080131887A1 (en) * | 2006-11-30 | 2008-06-05 | Stephan Dietrich A | Genetic Analysis Systems and Methods |
| WO2008112898A2 (en) * | 2007-03-13 | 2008-09-18 | The Children's Hospital Of Philadelphia | Genetic alterations on chromosome 12 and methods of use thereof for the diagnosis and treatment of type 1 diabetes |
-
2010
- 2010-08-20 CN CN201080047795.1A patent/CN102770140B/zh active Active
- 2010-08-20 HR HRP20161110TT patent/HRP20161110T1/hr unknown
- 2010-08-20 BR BR112012003653A patent/BR112012003653A2/pt not_active IP Right Cessation
- 2010-08-20 SI SI201031257A patent/SI2467140T1/sl unknown
- 2010-08-20 SG SG10201405039VA patent/SG10201405039VA/en unknown
- 2010-08-20 CA CA3080511A patent/CA3080511C/en active Active
- 2010-08-20 ES ES10810654.3T patent/ES2589377T3/es active Active
- 2010-08-20 AU AU2010284092A patent/AU2010284092A1/en not_active Abandoned
- 2010-08-20 LT LTEP10810654.3T patent/LT2467140T/lt unknown
- 2010-08-20 WO PCT/US2010/046142 patent/WO2011022633A2/en not_active Ceased
- 2010-08-20 ME MEP-2016-168A patent/ME02492B/me unknown
- 2010-08-20 JP JP2012525725A patent/JP5876827B2/ja active Active
- 2010-08-20 MX MX2012002161A patent/MX367580B/es active IP Right Grant
- 2010-08-20 CA CA2771699A patent/CA2771699C/en active Active
- 2010-08-20 US US13/391,579 patent/US20120156200A1/en not_active Abandoned
- 2010-08-20 PL PL10810654T patent/PL2467140T3/pl unknown
- 2010-08-20 PT PT108106543T patent/PT2467140T/pt unknown
- 2010-08-20 RS RS20160681A patent/RS55074B1/sr unknown
- 2010-08-20 SG SG2012010658A patent/SG178439A1/en unknown
- 2010-08-20 KR KR1020127007152A patent/KR101781658B1/ko not_active Expired - Fee Related
- 2010-08-20 EP EP10810654.3A patent/EP2467140B1/en not_active Revoked
- 2010-08-20 HU HUE10810654A patent/HUE029098T2/en unknown
- 2010-08-20 EA EA201270298A patent/EA027959B1/ru not_active IP Right Cessation
- 2010-08-20 DK DK10810654.3T patent/DK2467140T3/en active
-
2012
- 2012-02-15 ZA ZA2012/01110A patent/ZA201201110B/en unknown
- 2012-02-20 IL IL218230A patent/IL218230B/en active IP Right Grant
-
2014
- 2014-06-17 AU AU2014203270A patent/AU2014203270B2/en not_active Revoked
-
2015
- 2015-02-27 US US14/634,052 patent/US9539257B2/en active Active
-
2016
- 2016-09-01 SM SM201600296T patent/SMT201600296B/it unknown
- 2016-09-01 CY CY20161100861T patent/CY1118486T1/el unknown
- 2016-11-21 US US15/356,719 patent/US10004742B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wapner et al. | Expanding the scope of noninvasive prenatal testing: detection of fetal microdeletion syndromes | |
| Padyukov et al. | A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis | |
| Thachil et al. | Abnormal activation of autophagy-induced crinophagy in Paneth cells from patients with Crohn's disease | |
| Almén et al. | Genome-wide analysis reveals DNA methylation markers that vary with both age and obesity | |
| He et al. | Association between the HLA-B* 15: 02 allele and carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Han individuals of northeastern China | |
| Medrano et al. | Role of TNFRSF1B polymorphisms in the response of Crohn’s disease patients to infliximab | |
| ME02492B (me) | Lapatanib za lečenje kancera | |
| Jobim et al. | Analysis of KIR gene frequencies and HLA class I genotypes in breast cancer and control group | |
| Yin et al. | Prediction models for platinum-based chemotherapy response and toxicity in advanced NSCLC patients | |
| Ahn et al. | Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma | |
| Sivaram et al. | Macrophage migration inhibitory factor, Toll-like receptor 4, and CD14 polymorphisms with altered expression levels in patients with ulcerative colitis | |
| JP2013502433A5 (me) | ||
| Hayat et al. | Association of matrix metalloproteinase-9 polymorphism with severity of Guillain-Barré syndrome | |
| Cibeira et al. | Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide | |
| Søndergaard et al. | Genetic burden of MS risk variants distinguish patients from healthy individuals but are not associated with disease activity | |
| Kanai et al. | Large-scale prospective genome-wide association study of oxaliplatin in stage II/III colon cancer and neuropathy | |
| RU2014123166A (ru) | Восприимчивость к ингибиторам ангиогенеза | |
| JP2013526863A5 (me) | ||
| Rodríguez-Domínguez et al. | Spread of a new Chlamydia trachomatis variant from men who have sex with men to the heterosexual population after replacement and recombination in ompA and pmpH genes | |
| Christiansen et al. | Use of whole genome sequencing in the Dutch Acute HCV in HIV study: focus on transmitted antiviral resistance | |
| Lin et al. | Angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to osteoarthritis of the knee: a case-control study and meta-analysis | |
| Han et al. | Potential contribution of the neurodegenerative disorders risk loci to cognitive performance in an elderly male gout population | |
| AR104348A1 (es) | Polimorfismos de un solo nucleótido seleccionados que son predictivos de respuestas al acetato de glatirámero | |
| Wu et al. | Study of the tetraspanin 18 association with schizophrenia in a Han Chinese population | |
| AL-Damerchi et al. | Evaluation of A Disintegrin and Metalloprotein33 Gene Polymorphism in Bronchial Asthma |